Eisai to market Comtan and Stalevo in China

17 February 2017

Japan’s Eisai (TYO: 4523) has gained rights to market Parkinson's disease treatments Comtan (entacapone) and Stalevo (levodopa/entacapone/carbidopa combination agent) in China, following a deal with Finnish drugmaker Orion Corp (Nasdaq OMX: ORNAV).

Under the terms of the agreement, Eisai acquired from Orion the exclusive rights to market the two products in China, and began distribution and promotion through its Chinese subsidiary Eisai China.

Eisai has a diverse range of neurology products in China, including Parkinson's disease treatment Eldepryl (monoamine oxidase inhibitor), anti-Alzheimer's agent Aricept (donepezil) and the peripheral neuropathy treatment Methycobal (mecobalamin). Through the addition of Comtan and Stalevo, Eisai has strengthened its product line-up for Parkinson's disease treatment, and is now able to provide multiple treatment options with different mechanisms of action for patients with Parkinson's disease in China (around 1.7% of the population aged 65 years and over).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK